Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Sanofi India
Mid Cap•1,225 Employees•IPO 1994
Current Price
₹3716.70
-67.1 (-1.77%)Updated
Today's Range
₹3657.00
₹3749.00
₹3716.70
52 Week Range
52W Low₹3774.90
52W High₹6717.00
₹3716.70
Downside-1.54%
Upside80.72%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹9,272.57 Cr
Market Cap
Total market value of companyP/E Ratio
26.02
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
18.76
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹154.71
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
19.58%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
49.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
18.44%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-0.07%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-8.10%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
9.74%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
22.40%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.02
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹373.68
Book Value
Net asset value per shareDividend Yield
2.91%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
60.40%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Exceptional capital efficiency with ROE 47.1% and ROCE 49.2%.
- •Robust financial health, evidenced by a very low 0.02 debt-to-equity.
Weaknesses
5 points- •Declining quarterly net profit from ₹152M to ₹91M is concerning.
- •Negative EPS growth over 3Y (-24.11%) and 5Y (-0.07%) indicates earnings pressure.
Opportunities
5 points- •Robust pharmaceutical sector growth driven by increasing healthcare expenditure.
- •Rising chronic disease prevalence offers expanding market for treatments.
Threats
4 points- •Intense competition from major players could pressure market share.
- •Evolving regulatory policies, including drug price controls, pose risks.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹3942.13 | +₹225.43 | +6.07% |
| R3 | ₹3850.13 | +₹133.43 | +3.59% |
| R2 | ₹3799.57 | +₹82.87 | +2.23% |
| R1 | ₹3758.13 | +₹41.43 | +1.11% |
| PIVOT | ₹3707.57 | -9.13 | -0.25% |
| CURRENT | ₹3716.70 | - | - |
| S1 | ₹3482.13 | -₹234.57 | -6.31% |
| S2 | ₹3574.13 | -₹142.57 | -3.84% |
| S3 | ₹3615.57 | -₹101.13 | -2.72% |
| S4 | ₹3666.13 | -₹50.57 | -1.36% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-2.0% vs avg
0.20L
(09 Mar 2026)Delivery %+6.2% vs avg
60.3%
(09 Mar 2026)Avg Volume (20D)20-day average
0.20L
(09 Feb - 09 Mar)Avg Delivery %Trend ↓
54.1%
(09 Feb - 09 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Aarti Pharmalabs Ltd |
 Acutaas Chemicals Ltd |
 Aether Industries Ltd |
 Alivus Life Sciences Ltd |
 Blue Jet Healthcare Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 Granules India Ltd |
 Marksans Pharma Ltd |
 Natco Pharma Ltd |
 Procter & Gamble Health Ltd |
 |
 Sanofi Consumer Healthcare India Ltd |
 Shilpa Medicare Ltd |
 Strides Pharma Science Ltd |
 Sun Pharmaceutical Industries Ltd |
About
Sanofi India Ltd
Sanofi India Limited is a prominent pharmaceutical company with a significant global presence, operating in India, Singapore, and other international markets. Its core business revolves around the manufacturing, trade, and distribution of a diverse range of pharmaceutical products catering to various therapeutic areas.
The company's portfolio encompasses a wide spectrum of treatments, including medications for diabetes management (Lantus, Toujeo, Soliqua), cardiovascular health (Clexane, Cardace, Lasix), infectious diseases (Targocid), neurological conditions (Frisium), and other therapeutic areas such as allergy, pain management, digestive health, and nutritional support. These products are marketed under well-established brand names such as Amaryl, Lasilactone, Glimepiride, Cetapin, Combiflam, Allegra, Baralgan, and others.
Sanofi India's distribution network extends to numerous countries, with exports reaching approximately 24 different nations. This broad reach underscores the company's international standing and the demand for its products across diverse geographical regions. The company relies on a network of independent distributors to reach its target markets effectively.
With a history dating back to 1956, Sanofi India Limited has undergone name changes, previously operating as Aventis Pharma Limited before its current iteration. The company's headquarters are located in Mumbai, India, and it maintains its subsidiary status under Hoechst GmbH, highlighting its established position within the broader pharmaceutical industry.
COMPANY FACTS - SANOFI
Registered Address
Sanofi House, CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai
Mumbai
MAHARASHTRA
IN
Tel: 912228032000
Website:https://www.sanofi.com/en/india
Investor Relations:http://www.sanofiindialtd.com/en/investors/annual-reports
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,225
IPO Date: 28/11/1994
MANAGEMENT - SANOFI
Mr. Aditya Narayan
Independent Non-Executive Chairman of the Board
Mr. Surendra Agarwall
Chief Financial Officer, Whole-Time Director
Mr. Rodolfo Hrosz
Managing Director, Whole Time Director
Mr. Himanshu Bakshi
Managing Director
Ms. Renee Amonkar
Whole Time Director
Mr. N Babu
Sales & Customer Engagement Head - Diabetes
Mr. Bratin Bag
Senior Director - Ethics and Business Integrity, South Asia
Ms. Surabhi Kaul
Director - People and Culture, India
Ms. Yasmin Shenoy
Senior Director - Regulatory Affairs
Mr. Linumon Thomas
Digital Leader, India
Mr. Nakul Verma
Senior Director - Public Affairs
Ms. Radhika Shah
Company Secretary, Head of Legal
Investor Questions Answered
Sanofi India Ltd (SANOFI) Stock FAQs
Get answers to the most common questions about Sanofi India Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Sanofi India Ltd (SANOFI) is ₹3,716.7. Today, the stock has declined by ₹67.10 (1.77%), trading in a range of ₹3,657 to ₹3,749. The stock opened at ₹3,711 with a trading volume of 19,823 shares.
Sanofi India Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,272.57 crores, P/E ratio of 26.02, ROE of 19.58%, and ROCE of 49.20%. The dividend yield stands at 2.91%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Sanofi India Ltd (SANOFI) is ₹6,717, while the 52-week low is ₹3,774.9. Currently trading at ₹3,716.7, the stock is -2.0% away from its 52-week low and 44.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Sanofi India Ltd stock at ₹3,716.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.02 and P/B ratio of N/A. Today's performance shows a loss of 1.77%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Sanofi India Ltd offers a dividend yield of 2.91%, which means for every ₹100 invested at the current price of ₹3,716.7, you can expect to receive approximately ₹2.91 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Sanofi India Ltd's key financial metrics include: P/E Ratio: 26.02, P/B Ratio: N/A, ROE: 19.58%, ROCE: 49.20%, Dividend Yield: 2.91%, EPS: ₹154.71, Book Value: ₹373.68, Debt-to-Equity: 0.02, and Current Ratio: N/A. The company's market cap stands at ₹9,272.57 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Sanofi India Ltd stock opened at ₹3,711 and is currently trading at ₹3,716.7, showing a decline of ₹67.10 (1.77%). The intraday high is ₹3,749 and low is ₹3,657. The trading volume stands at 19,823 shares, indicating moderate market participation today.
Sanofi India Ltd has a Price-to-Earnings (P/E) ratio of 26.02, which means investors are willing to pay ₹26.02 for every ₹1 of earnings. With an EPS of ₹154.71, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Sanofi India Ltd has a market capitalization of ₹9,272.57 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹3,716.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Sanofi India Ltd has a book value of ₹373.68 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹3,716.7, which is 894.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Sanofi India Ltd has a Return on Equity (ROE) of 19.58% and Return on Capital Employed (ROCE) of 49.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. Both metrics are strong, indicating efficient capital utilization. Higher percentages generally indicate better financial performance.
Sanofi India Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Sanofi India Ltd has a debt-to-equity ratio of 0.02, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Sanofi India Ltd has an Earnings Per Share (EPS) of ₹154.71, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹3,716.7 and P/E ratio of 26.02, investors are paying 26.02 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Sanofi India Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Sanofi India Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Sanofi India Ltd stock, consider: 1) Fundamental Analysis - Review P/E (26.02), ROE (19.58%), debt-to-equity (0.02), and growth rates. 2) Technical Analysis - Check 52-week range (₹3774.90 - ₹6717.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹3716.70) with book value (₹373.68) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Sanofi India Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹3,716.7 is 37067x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Sanofi India Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹3774.90 - ₹6717.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.02 indicates leverage. 4) Liquidity Risk - Based on trading volume of 19,823 shares. 5) Valuation Risk - P/E of 26.02 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Sanofi India Ltd operates in the industry with key metrics: P/E ratio of 26.02, ROE of 19.58%, market cap of ₹9,272.57 crores, and dividend yield of 2.91%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.02), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Sanofi India Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹3,716.7, with a 52-week range of ₹3774.90 to ₹6717.00. Based on fundamentals like P/E (26.02), ROE (19.58%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Sanofi India Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹3716.70. 2) Fundamental Deterioration - Declining ROE (currently 19.58%), increasing debt (D/E: 0.02), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Sanofi India Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 2.91%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu